AGIO
$28.91
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Recent News
Servier’s $2.5B cancer bet underlines a quick oncology growth strategy
Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets
The updated fair value estimate for Agios Pharmaceuticals has shifted to US$38.88 from US$36.75, while several bullish analysts are now guiding price targets into the mid US$20s to mid US$30s. Those targets are being framed around the recent approval of Aqvesme, sector conditions in biotech, and differing views on how much risk to assign at current levels, with JPMorgan holding a Neutral stance alongside a US$25 target. As you read on, you will see how these moving targets fit into the...
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction
Agios Pharmaceuticals (NASDAQ:AGIO) executives highlighted multiple upcoming clinical and regulatory milestones during the 46th Annual TD Cowen Healthcare Conference, while also discussing early launch indicators following the company’s thalassemia approval for mitapivat. Management outlines 2026 c
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.